(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603567 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates a substantial decrease in revenue and net profit compared to the same period last year, reflecting challenges in sales performance. The company also reported a notable decline in cash flow from operating activities, attributed to reduced sales collections. The financial statements included in the report have not been audited, and the board assures the accuracy and completeness of the information provided.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
HeiLongJiang ZBD Pharmaceutical Co., Ltd. on 6ix
Earlier from HeiLongJiang ZBD Pharmaceutical
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Departure of the Director and Board Secretary and Designation of the Chairman to Act as the Board Secretary
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Notice on Convening the 5th Extraordinary General Meeting in 2026
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Termination of Certain Raised Funds Investment Projects and Continued Deposit of Remaining Raised Funds in Special Accounts for Raised Funds
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 6th Board of Directors
Later from HeiLongJiang ZBD Pharmaceutical
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on the Branch's Receipt of the Approval Notice for the Marketing Application of a Chemical API
- (603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Resolutions of the 5th Extraordinary General Meeting in 2026
Follow HeiLongJiang ZBD Pharmaceutical into a list and get an email when it puts out news.
Follow HeiLongJiang ZBD Pharmaceutical